|1.||Li, Gang: 1 article (11/2015)|
|2.||Lau, Carol P Y: 1 article (11/2015)|
|3.||Tsui, Stephen K W: 1 article (11/2015)|
|4.||Huang, Lin: 1 article (11/2015)|
|5.||Wong, Kwok Chuen: 1 article (11/2015)|
|6.||Kumta, Shekhar Madhukar: 1 article (11/2015)|
|7.||Tao, Yunting: 1 article (07/2015)|
|8.||Yang, Jay: 1 article (07/2015)|
|9.||Chu, Uyen B: 1 article (07/2015)|
|10.||Weaver, Sara J: 1 article (07/2015)|
09/01/2005 - "Furthermore, the treatment of B16F10 cells with GGTI-298 or C3 exoenzyme associated with mIFN-gamma induces in vivo tumor growth slowing down in immunocompetent but not in nu/nu syngeneic mice. "
01/01/2003 - "The treatment of cancer cells with GGTI-298 markedly caused RhoA to decrease in the membrane fraction and accumulate in the cytosolic fraction, whereas it had almost no effect on the translocation of Ras. "
03/12/1999 - "In the present manuscript, we provide a possible mechanism by which GGTI-298 mediates its tumor growth arrest. "
01/01/2010 - "In this study, it is shown that vaccination with mIFN-gand GGTI-298 pretreated B16F10 cells induces a protection against untreated tumor growth and pulmonary metastases implantation. "
01/01/2010 - "These data indicate that pharmacological treatment of melanoma cell lines with IFN-gamma and GGTI-298 stimulates their immunogenicity and could be a novel approach to produce tumor cells suitable for vaccination and for stimulation of anti-melanoma effector cells."
|2.||Neoplasm Metastasis (Metastasis)
07/01/1998 - "Our studies demonstrated that FTI-277, GGTI-286, and GGTI-298 each yielded significant antiproliferative effects in human malignant glioma cells in vitro at low micromolar concentrations, which have been achievable in vivo without major systemic toxicity. "
07/01/1998 - "FTI-277, GGTI-286, and GGTI-298 each produced a striking concentration-dependent antiproliferative effect on the glioma cell lines, with the median effective dose ranging from 2.5 to 15.5 micromol/L. "
12/01/1998 - "Here, we show that GGTI-298 acts at the transcriptional level to induce p21(WAF1/CIP1) in a human pancreatic carcinoma cell line, Panc-1. "
03/12/1999 - "Treatment of the human lung carcinoma cell line Calu-1 with GGTI-298 results in inhibition of the phosphorylation of retinoblastoma protein, a critical step for G1/S transition. "
|5.||Breast Neoplasms (Breast Cancer)
01/01/2015 - "Importantly, atorvastatin or the geranylgeranyltransferase I inhibitor GGTI-298 inhibited breast cancer cell proliferation through inactivation of YAP signaling and down-regulation of PBK. "
01/15/2006 - "Using breast tumor models, we show that agents possessing a lactone moiety, including statins (such as lovastatin) and the isoprenoid inhibitors (such as FTI-277 and GGTI-298), mediate their cell cycle inhibitory activities by blocking the chymotrypsin activity of the proteasome in vitro. "
|3.||geranylgeranyltransferase type-I (protein geranylgeranyltransferase)
|9.||Cyclin-Dependent Kinase Inhibitor p21
|10.||Proteasome Endopeptidase Complex (Proteasome)